Results for this period
Interim period (second quarter)1 January 2026–30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Year-on-year comparisons have not been provided because the comparative periods differ due to the change in the fiscal year-end. The Company is in an early investment phase focused on research and development, with no products launched. As a result of recording research and development expenses of ¥239.806 million and other selling, general and administrative expenses of ¥152.455 million, the operating loss was ¥392.262 million.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–30 June 2026 |
| Operating profit | ¥-392 million |
| Ordinary income | ¥-392 million |
| Profit attributable to owners of the parent | ¥-393 million |
| Net income per share | -¥8.64 |
| Equity ratio | End of the current fiscal period 93.9 / End of previous period 95.5 |
| Total assets | ¥2,514 million |
| Net assets | ¥2,410 million |
| Cash flows from operating activities | ¥-339,104 thousand |
| Cash flows from investing activities | ¥-641 thousand |
| Cash flows from financing activities | ¥17,842 thousand |
| Cash and cash equivalents at end of period | ¥2,459,128 thousand |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Remarks No earnings forecast has been provided because it is difficult to formulate a reasonable earnings forecast. |
| Annual Dividend Forecast | ¥0.00 → ¥0.00 |
| Depreciation and amortization | ¥57 thousand |
| Impairment loss | ¥584 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Impairment Losses ¥584 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 45,666,567 Shares |
| Treasury Shares at Period-End | 10 Shares |
| Factors Behind Changes in Business Performance | Year-on-year comparisons have not been provided because the comparative periods differ due to the change in the fiscal year-end. The Company is in an early investment phase focused on research and development, with no products launched. As a result of recording research and development expenses of ¥239.806 million and other selling, general and administrative expenses of ¥152.455 million, the operating loss was ¥392.262 million. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explains that it is in an early investment phase focused on research and development, with no products launched, and recorded research and development expenses of ¥239.806 million and other selling, general and administrative expenses of ¥152.455 million. It is also advancing the development and expansion of its pipeline, including TMS-007 and TMS-008.